Stories

La semaglutida oral reduce el riesgo de eventos de insuficiencia cardiaca en personas con diabetes tipo 2

By Angela Yeager February 26, 2026

El estudio dirigido por OHSU muestra una reducción de las hospitalizaciones y muertes relacionadas con insuficiencia cardiaca en personas con alto riesgo.

Oral semaglutide lowers risk of heart failure events in people with Type 2 diabetes

By Angela Yeager February 26, 2026

The OHSU-led study shows reduced heart failure-related hospitalizations, deaths in high-risk individuals.

Weekly semaglutide improves blood sugar and weight in adults with Type 1 diabetes

By Angela Yeager June 23, 2025

A double-blind clinical trial shows promising results.

La semaglutida semanal mejora el azúcar en sangre y el peso en adultos con diabetes tipo 1

By Angela Yeager June 23, 2025

Un ensayo clínico doble ciego muestra resultados prometedores.

$2.1 million gift enhances OHSU center’s efforts to combat diabetes

By Erik Robinson June 12, 2025

Real estate developer and philanthropist Jordan Schnitzer provides gift to center previously established by his parents.

Low-income patients with diabetes are more likely to experience insurance instability

By Angela Yeager April 18, 2025

Researchers find people who lose Medicaid coverage also likely to remain uninsured, especially those with the most complex needs.

Artificial intelligence, diabetes experts combine forces for blood sugar management study

By Franny White January 10, 2023

Smartphone app being improved to better help patients control their type 1 diabetes.

New algorithm uses artificial intelligence to help manage type 1 diabetes

By Erik Robinson June 12, 2020

OHSU algorithm could be useful in maintaining safe levels of glucose.

Inspiring youth to create technology solutions for diabetes care

By Franny White May 17, 2018

OHSU diabetes and clinical nutrition experts help Beaverton students in health tech challenge.

Discovery of insulin-producing beta cell subtypes may impact diabetes treatment

July 11, 2016

A new study led by nationally prominent stem cell scientist Markus Grompe, M.D., has determined the existence of at least four separate subtypes of human insulin producing beta cells that may be important in the understanding and treatment of ...

Stories

OHSU in the News